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ABSTRACT
Objectives: Estimate survival after acute myocardial
infarction (AMI) in the general population aged 60 and
over and the effect of recommended treatments.
Design: Cohort study in the UK with routinely
collected data between January 1987 and March 2011.
Setting: 310 general practices that contributed to The
Health Improvement Network (THIN) database.
Participants: 4 cohorts who reached the age of 60,
65, 70, or 75 years between 1987 and 2011 included
16 744, 43 528, 73 728, and 76 392 participants,
respectively. Participants with a history of AMI were
matched on sex, year of birth, and general practice to 3
controls each.
Outcome measures: The hazard of all-cause
mortality associated with AMI was calculated by a
multilevel Cox’s proportional hazards regression,
adjusted for sex, year of birth, socioeconomic status,
angina, heart failure, other cardiovascular conditions,
chronic kidney disease, diabetes, hypertension,
hypercholesterolaemia, alcohol consumption, body
mass index, smoking status, coronary
revascularisation, prescription of β-blockers, ACE
inhibitors, calcium-channel blockers, aspirin, or statins,
and general practice.
Results: Compared with no history of AMI by age 60,
65, 70, or 75, having had 1 AMI was associated with
an adjusted hazard of mortality of 1.80 (95% CI 1.60
to 2.02), 1.71 (1.59 to 1.84), 1.50 (1.42 to 1.59), or
1.45 (1.38 to 1.53), respectively, and having had
multiple AMIs with a hazard of 1.92 (1.60 to 2.29),
1.87 (1.68 to 2.07), 1.66 (1.53 to 1.80), or 1.63 (1.51
to 1.76), respectively. Survival was better after statins
(HR range across the 4 cohorts 0.74–0.81), β-blockers
(0.79–0.85), or coronary revascularisation (in first
5 years) (0.72–0.80); unchanged after calcium-channel
blockers (1.00–1.07); and worse after aspirin (1.05–
1.10) or ACE inhibitors (1.10–1.25).
Conclusions: The hazard of death after AMI is less
than reported by previous studies, and standard
treatments of aspirin or ACE inhibitors prescription
may be of little benefit or even cause harm.
INTRODUCTION
Survival after acute myocardial infarction
(AMI) has improved over the past decades in
Western countries including the UK both in
the short and long term,1–6 partly due to an
increase in coronary revascularisation, more
effective drug therapy, and healthier life-
styles.1–3 6 7 The prevalence of AMI has
increased, partly due to the ageing popula-
tion, which makes evaluating long-term sur-
vival prospects increasingly important for
setting out healthcare requirements and
resource planning. Previous studies have esti-
mated mortality rates of AMI standardised
for age, sex, deprivation or region2–6 and
examined survival variations in AMI patients,
usually selected patients through hospitals or
registries, by a range of confounders.1 2 5 7–12
A recent population-based cohort study in
England with data from 2004 to 2010 con-
cluded that after 7 years people with a ﬁrst
or recurrent AMI had double or triple the
risk of mortality compared with the general
population of equivalent sex and age.5 These
hazards are likely to be overestimated,
because the study did not include
controls and could therefore only compare
the results with the sex-standardised and
age-standardised mortality rates of the
general population. AMI patients may be
more likely to have comorbidities and an
unhealthy lifestyle, which are independent
Strengths and limitations of this study
▪ Large cohort study representative of the full
range of patients seen in routine clinical practice
in the UK, which has a better coverage of acute
myocardial infarction (AMI) patients than hos-
pital records or disease registers.
▪ The matched study design allowed to estimate
the effect of a history of AMI on all-cause mor-
tality compared with no history of AMI while
adjusting for a wide range of confounders.
▪ Although the major confounders of AMI were
adjusted for, there could potentially be some
residual confounding by indication for the
treatments.
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predictors of survival, and so adjustment for these con-
founders is important.13–15
There is a need for a study that estimates long-term
survival prospects after AMI, adjusts for important con-
founders, and assesses the impact of treatments on sur-
vival. With primary care data, information on
demographics, lifestyle factors, comorbidities, and treat-
ments is available for both cases and controls, thus allow-
ing to estimate the adjusted survival difference between
the two groups. Additionally, primary care has a better
coverage of patients with AMI than hospitals and regis-
ters, because it includes patients who were diagnosed
immediately and patients who were not sent to the hos-
pital but were diagnosed in routine practice later by
blood test results.16 Between 2003 and 2009, primary
care covered 75% of the AMI cases in England while
hospital and register data covered 68% and 52%,
respectively.16 The three data sources had similar preva-
lence of risk factors and mortality rates of AMI.16
The objectives of this study were to estimate the
hazard of mortality associated with a history of a single
or multiple AMIs at key ages in UK residents while con-
trolling for a wide range of confounders, and to estimate
how survival prospects of AMI patients were changed by
coronary revascularisation and recommended drug
therapy.
METHODS
Study design
This matched cohort study made use of medical records
from The Health Improvement Network (THIN) data-
base. These records are representative of the UK popula-
tion regarding demographics, prevalence of medical
conditions, and mortality rates when adjusted for
deprivation.17 18
Four cohorts of patients who were born between 1920
and 1940 and turned the initial age in 1987–2011 were
selected. The initial ages were 60, 65, 70, and 75, chosen
to provide advice on future management plans and
resource planning at key ages.14 The selected patients
had to be registered for at least 1 year at a general prac-
tice that coded death dates validly. The patient’s record
had to include a postcode and should have been
accessed at least once within the past 10 years. From
these cohorts, patients with a history of AMI were
selected and each was matched to three controls without
history on sex, year of birth category, and general prac-
tice. The study’s end date was the 18th of March 2011,
thus patients were followed-up for up to 24 years.
Patients could be part of multiple cohorts. Patients who
changed general practice during the study could no
longer be observed. It was assumed that the loss to
follow-up was not associated with the outcome mortality.
Patient involvement
No patient was involved in setting the research question,
outcome measures, design or conduct of the study. The
results were not disseminated to the patients, as the
study was based on anonymised patient records.
Variable selection
The baseline characteristics of patients were assessed on
the 1st of January of the year they turned the cohort’s
age. The primary exposure was AMI. Multiple events
were required to be separated by 30 days. Information
on the type of AMI was not available. However, a study
that linked information from the Myocardial Ischaemia
National Audit Project (MINAP) and the General
Practice Research Database (GPRD), which has 60% of
practices in overlap with THIN, found that 46% of AMIs
were ST-elevated (ST segment elevation myocardial
infarctions, STEMIs) in England and Wales in
2003–2008.19 The selected confounders were based on
literature review, and consisted of: sex, year of birth,
socioeconomic status, angina pectoris, heart failure,
other cardiovascular conditions (valvular heart disease,
peripheral vascular disease, and cerebrovascular
disease), chronic kidney disease, diabetes mellitus,
hypertension, hypercholesterolaemia, alcohol consump-
tion, body mass index (BMI), and smoking status (see
online supplementary tables SA1 and SA2).
Socioeconomic status was measured by Mosaic, which is
based on demographics, lifestyles, and behaviour of
people at a postcode level.20
The treatment investigated was based on the UK
National Institute of Health and Care Excellence
(NICE) recommended ﬁrst-line treatment to AMI
patients during the study period, which includes: coron-
ary revascularisation and prescription of ACE inhibitors,
aspirin, β-blockers, calcium-channel blockers, and
statins.21–23 Since 2007, calcium-channel blockers are
only recommended to treat hypertension or angina in
AMI patients.22 23 Since 2013, dual antiplatelet therapy
(DAPT: aspirin plus another antiplatelet agent) are rec-
ommend to AMI patients.22 23 Owing to the low preva-
lence of DAPT in the age cohorts, the survival effect of
the therapy were not estimated (see online
supplementary table SA3). Family history of AMI or car-
diovascular disease were not included in the analysis
because of the very low rates of recording in primary
care.24 Indicators of psychosocial factors such as job
strain and lack of social support, fruit and vegetable
intake, and physical activity were not included in the
analysis because THIN does not hold information on
them.
There were missing values in alcohol consumption
(proportion range across the four cohorts 17–37%),
BMI (18–37%), and smoking status (10–29%). The frac-
tion of incomplete medical records decreased with age;
45% of the youngest cohort and 23% of the oldest
cohort had incomplete records. Incomplete records
were more common in patients born at an earlier year
and in patients without medical conditions or on treat-
ments (see online supplementary table SA4). This is in
accordance with previous research that reported that
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recording has improved since the introduction of
Quality and Outcomes Framework (QOF) in 2004.25–27
Missing values were dealt with by multiple imputation.28
The distribution of known and imputed values were
similar (see online supplementary table SA5).
Statistical analyses
A Cox’s proportional hazards regression model was
ﬁtted to estimate the effect of a history of AMI and
respective treatments on the hazard of all-cause mortal-
ity at different ages. The outcome variable was time to
death in days, that is, from 1st of January of the year the
patient turned the cohort’s age to the date of death.
Starting from a model with second-order interaction
effects of all variables with the main exposure AMI and
the matching factors sex and year of birth, backward
elimination was performed to obtain the most parsimo-
nious model possible. Interaction effects found in the
complete case analysis, that is, the analysis that excluded
patients with incomplete medical records, which were
not restricted to the main exposure and matching
factors, were also included in the backward elimination
process. A uniﬁed model for all ages was chosen to have
the same interpretation of the hazards.
The ﬁnal model included sex, year of birth,
socioeconomic status, AMI, angina, heart failure, other
cardiovascular conditions, chronic kidney disease, dia-
betes, hypertension, hypercholesterolaemia, coronary
revascularisation, β-blockers, ACE inhibitors, calcium-
channel blockers, aspirin, statins, alcohol consumption,
BMI, smoking status, general practice, and interactions
of AMI with angina, AMI with β-blockers, AMI with
calcium-channel blockers, hypercholesterolaemia with
statins, and BMI with smoking status. Chronic kidney
disease was not adjusted for at ages 60 and 65 due to low
prevalence of <1%.
The number of years gained or lost due to a history of
AMI, coronary revascularisation, and drug therapy were
calculated.29 The models were assessed on validity of pro-
portional hazards assumption, overall performance, dis-
crimination, and external validation.30–32 The sensitivity
analysis compared the unadjusted and adjusted effect of
a history of AMI estimated on the imputed datasets.
For more detailed information on the statistical ana-
lyses, please see online supplementary data.
RESULTS
The prevalence of comorbidities was higher among AMI
cases than controls (ﬁgure 1 and table 1). Obesity
(BMI≥30 kg/m2) was more common among cases,
whereas overweight (BMI 25–30 kg/m2) was as common
among cases as controls. The prevalence of smokers was
the same in the two groups, while the prevalence of
ex-smokers was greater among cases.
Prevalence of treatment
The prevalence of coronary revascularisation and drug
therapy was higher among patients who had multiple
AMIs compared with patients who had a single AMI
(table 2). The rates across the four age cohorts for
Figure 1 Selection of cohorts. AMI, acute myocardial infarction.
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Table 1 Characteristics of acute myocardial infarction (AMI) cases and controls by age cohort
Age 60 Age 65 Age 70 Age 75
Cases* Controls† Cases Controls Cases Controls Cases Controls
Number of participants 4186 12 558 10 882 32 646 18 432 55 296 19 098 57 294
Total person-years of follow-up (mean) 46 686 (11.2) 150 471 (12.0) 93 056 (8.6) 299 841 (9.2) 114 700 (6.2) 370 006 (6.7) 91 884 (4.8) 298 140 (5.2)
Deaths during follow-up (%) 1220 (29%) 2008 (16%) 3070 (28%) 5782 (18%) 5186 (28%) 10 557 (19%) 5895 (31%) 12 674 (22%)
Transferred during follow-up (%) 900 (22%) 3035 (24%) 1986 (18%) 6597 (20%) 2693 (15%) 8781 (16%) 2733 (14%) 8971 (16%)
Male (%) 3367 (80%) 10 101 (80%) 8402 (77%) 25 206 (77%) 13 567 (74%) 40 701 (74%) 13 163 (69%) 39 489 (69%)
Angina (%) 1924 (46%) 594 (5%) 5161 (47%) 2445 (7%) 8623 (47%) 5528 (10%) 9122 (48%) 7472 (13%)
Heart failure (%) 205 (5%) 61 (0%) 676 (6%) 338 (1%) 1568 (9%) 982 (2%) 2198 (12%) 1674 (3%)
Other cardiovascular conditions (%) 979 (23%) 681 (5%) 3154 (29%) 2941 (9%) 6591 (36%) 7672 (14%) 8205 (43%) 11 674 (20%)
Chronic kidney disease (%) 1 (0%) 0 (0%) 4 (0%) 8 (0%) 965 (5%) 1392 (3%) 1872 (10%) 3039 (5%)
Diabetes (%) 449 (11%) 624 (5%) 1622 (15%) 2297 (7%) 3398 (18%) 5573 (10%) 3726 (20%) 6876 (12%)
Hypercholesterolaemia (%) 1634 (39%) 1907 (15%) 4228 (39%) 7423 (23%) 6392 (35%) 14 936 (27%) 6395 (33%) 15 814 (28%)
Hypertension (%) 1168 (28%) 1991 (16%) 3750 (34%) 7608 (23%) 7411 (40%) 17 955 (32%) 8579 (45%) 22 330 (39%)
Alcohol consumer (%)‡ 3385 (81%) 10 997 (88%) 8780 (81%) 28 130 (86%) 14 494 (79%) 45 962 (83%) 14 293 (75%) 45 504 (79%)
Overweight (%)‡ 2427 (58%) 7239 (58%) 5866 (54%) 17 609 (54%) 9406 (51%) 28 253 (51%) 9264 (49%) 28 030 (49%)
Obese (%)‡ 750 (18%) 1418 (11%) 2295 (21%) 4687 (14%) 4107 (22%) 9180 (17%) 3848 (20%) 9365 (16%)
Ex-smoker (%)‡ 1274 (30%) 2398 (19%) 4611 (42%) 10 903 (33%) 8335 (45%) 19 305 (35%) 8695 (46%) 20 641 (36%)
Smoker (%)‡ 1163 (28%) 3507 (28%) 2203 (20%) 6544 (20%) 3079 (17%) 8973 (16%) 2545 (13%) 7660 (13%)
*Participants with a history of AMI.
†Participants with no history of AMI.
‡Mean 10 imputed datasets.
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coronary artery bypass graft (CABG) and percutaneous
coronary intervention (PCI) were 16–19% and 3–8%,
respectively (see online supplementary table SA6). Men
were approximately twice as likely to have had coronary
revascularisation as women were, which could not be
explained by age, deprivation, or diabetes (see online
supplementary ﬁgure SA1 and table SA7). Men and
women were equally likely to be prescribed drugs. From
1995 to 2011, the prevalence of coronary revascularisa-
tion and drug therapy increased substantially, with the
exception of prescription of calcium-channel blockers
which decreased over the years (see online
supplementary ﬁgure SA2). The difference in treatment
prevalence by the four initial ages converged over time.
In 2010 the most widely prescribed drugs to AMI
patients were statins (94%) and aspirin (94%) followed
by ACE inhibitors (85%), β-blockers (65%), and
calcium-channel blockers (25%). In the same year, 38%
of the AMI patients have had coronary revascularisation
by an initial age; the prevalence was greater in patients
living in the most afﬂuent areas (index of multiple
deprivation (IMD) category 1: 45%) than in patients
living in the most deprived areas (IMD category 5:
32%), trend χ2 (1)=5.06, p=0.02.
Survival prospects after AMI
The adjusted hazard of all-cause mortality for AMI
patients was constant during follow-up of 24 years; it did
not matter how many years the cases had already sur-
vived, they were still at a higher risk of dying than the
controls. This relative risk was the greatest in the young-
est cohort while the absolute risk was the greatest in the
oldest cohort (ﬁgure 2 and see online supplementary
ﬁgure SA3). Compared with no history of AMI by age
60, 65, 70, or 75, having had one AMI was associated
with an adjusted hazard of mortality of 1.8 (1.6 to 2.0),
1.7 (1.6 to 1.8), 1.5 (1.4 to 1.6), or 1.5 (1.4 to 1.5),
respectively. This translates to a decrease in life expect-
ancy of 5.9 (4.7 to 7.0), 5.4 (4.6 to 6.1), 4.1 (3.5 to 4.6),
and 3.7 (3.2 to 4.3) years, respectively. Compared with
no history of AMI by age 60, 65, 70, or 75, having had
multiple AMIs was associated with an adjusted hazard of
mortality of 1.9 (1.6 to 2.3), 1.9 (1.7 to 2.0), 1.66 (1.5 to
1.8), or 1.6 (1.5 to 1.8), respectively. This translates to a
decrease in life expectancy of 6.5 (4.7 to 8.3), 6.2 (5.2 to
7.3), 5.1 (4.3 to 5.9), or 4.9 (4.1 to 5.6) years, respect-
ively. The hazard of mortality did not differ between
cases with or without a history of angina. There were
also interactions with prescriptions of β-blockers and
calcium-channel blockers, which are described below.
There were no other interactions with a history of AMI,
meaning that the effect of AMI on the hazard of mortal-
ity was the same for different groups of patients, such as
for men and women. The comorbidities that had the
greatest impact on survival were other cardiovascular
conditions and heart failure (see online supplementary
Table 2 Baseline treatment given a possible history of IHD
Coronary
revascularisation Drug therapy
Cohort* IHD Size Men Women Aspirin
ACE
inhibitors β-blockers Statins
Ca-channel
blockers†
Age 60 No 11 964 0 (0%) 0 (0%) 271 (2%) 678 (6%) 1156 (10%) 208 (2%) 615 (5%)
Angina 594 97 (19%) 7 (8%) 211 (36%) 95 (16%) 238 (40%) 148 (25%) 264 (44%)
Single AMI 3465 486 (18%) 77 (11%) 1467 (42%) 768 (22%) 1482 (43%) 951 (27%) 1080 (31%)
Multiple
AMIs
721 194 (32%) 20 (18%) 386 (54%) 256 (36%) 314 (44%) 247 (34%) 290 (40%)
Age 65 No 30 201 0 (0%) 0 (0%) 2548 (8%) 3299 (11%) 3727 (12%) 2194 (7%) 2709 (9%)
Angina 2445 512 (25%) 30 (7%) 1400 (57%) 701 (29%) 1036 (42%) 1164 (48%) 1024 (42%)
Single AMI 8796 1532 (23%) 334 (16%) 5751 (65%) 3452 (39%) 4011 (46%) 4722 (54%) 2762 (31%)
Multiple
AMIs
2086 594 (35%) 67 (17%) 1532 (73%) 1072 (51%) 946 (45%) 1272 (61%) 722 (35%)
Age 70 No 49 768 0 (0%) 0 (0%) 8698 (17%) 9756 (20%) 7176 (14%) 8863 (18%) 6820 (14%)
Angina 5528 1263 (28%) 125 (12%) 3851 (70%) 2204 (40%) 2376 (43%) 3335 (60%) 2235 (40%)
Single AMI 14 847 2811 (26%) 730 (18%) 11 269 (76%) 7770 (52%) 6989 (47%) 9638 (65%) 4461 (30%)
Multiple
AMIs
3585 1012 (36%) 172 (22%) 2918 (81%) 2202 (61%) 1721 (48%) 2524 (70%) 1219 (34%)
Age 75 No 49 822 0 (0%) 0 (0%) 12 592 (25%) 12 633 (25%) 7945 (16%) 11 318 (23%) 8574 (17%)
Angina 7472 1652 (29%) 225 (13%) 5642 (76%) 3430 (46%) 3188 (43%) 4780 (64%) 2952 (40%)
Single AMI 15 319 2705 (26%) 835 (17%) 12 487 (82%) 9226 (60%) 7036 (46%) 10 395 (68%) 4676 (31%)
Multiple
AMIs
3779 954 (35%) 230 (23%) 3295 (87%) 2574 (68%) 1759 (47%) 2767 (73%) 1228 (32%)
*The age cohorts included cases with history of AMI who were matched to three controls on sex, year of birth category, and general practice.
The prevalence of treatment by the initial ages was affected by calendar year (see online supplementary figure SA2).
†First-line drugs prescription until 2007 after which it became a second-line drugs prescription.2
AMI, acute myocardial infarction; IHD, ischaemic heart disease.
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ﬁgures SA4–7). The associated impact was greatest in
the youngest age cohort. On average the comorbidities
led to an additional decrease in life expectancy of 4.6–
7.1 years.
Coronary revascularisation was associated with a sig-
niﬁcant improvement in the survival prospects in the
short-term (ﬁgure 3). Compared with no history of cor-
onary revascularisation by age 60, 65, 70, or 75, having
had revascularisation was associated with an adjusted
hazard of mortality of 0.8 (0.6 to 1.1), 0.7 (0.6 to 0.8),
0.7 (0.7 to 0.8), and 0.8 (0.7 to 0.8), respectively, in the
ﬁrst 5 years of follow-up. This translates to an increase in
life expectancy of 2.3 (−0.5 to 5.0), 3.3 (2.0 to 4.7), 3.1
(2.2 to 4.0), and 2.5 (1.7 to 3.2) years, respectively. After
5 years of follow-up, a history of coronary revascularisa-
tion was no longer associated with a signiﬁcant improve-
ment in the survival prospects. These prospects were the
same for men and women.
Drug therapy was associated with mixed survival
prospects and could differ by subgroups of patients
(ﬁgure 3). The drug therapy that was associated with
the greatest improved survival prospects was prescription
of statins; the prescription translated to an average
increase in life expectancy of 2.5 years at all ages. The
hazard of mortality associated with statins prescription
did not differ between patients with or without a history
of hypercholesterolaemia. Prescription of β-blockers was
associated with mixed survival prospects; prescription
translated to an average increase in life expectancy of
2.0 years at all ages in AMI patients versus no increase in
patients without AMI. Prescription of calcium-channel
blockers was also associated with mixed survival pro-
spects; prescription translated to no increase in life
expectancy in AMI patients versus an average decrease
in life expectancy of 2.0 years in patients without AMI.
Prescription of aspirin or ACE inhibitors was associated
with worsened survival prospects; the prescription trans-
lated to an average decrease in life expectancy of 1.0
and 1.5 years, respectively, at all ages. There were no sig-
niﬁcant differences in the effects of the treatments by
sex.
Survival prospects differed by socioeconomic status, in
which the difference was greater at a younger age. The
Mosaic category 5 (‘neighbourhood with mainly young
couples’) was associated with the worst survival prospects
for patients aged 60 and older, this ranged from an
adjusted hazard of mortality of 1.7 (1.4 to 2.1) at age 60
to 1.3 (1.2 to 1.4) at age 75 (see online supplementary
ﬁgures SA3–6). In addition, survival prospects varied
considerably between general practices. The 95% toler-
ance interval of the adjusted hazard of mortality asso-
ciated with general practice was 0.8 to 1.2 at age 60 and
0.6 to 1.5 at older age. This translates to an average of
4.5 and 10.0 years difference in life expectancy, respect-
ively. A general practice could serve a range of patients
with regards to health status, ethnic background, depriv-
ation, urbanisation, and pollution. These factors,
however, did not explain the hazard of mortality asso-
ciated with general practice (see online supplementary
methods and table SA8).
Model performance
Please see the online supplementary data for model per-
formance and sensitivity analysis.
DISCUSSION
This matched cohort study estimated the adjusted
hazard of all-cause mortality associated with a history of
AMI and respective treatments by age 60, 65, 70, or 75
in UK residents using medical records from primary
care between 1987 and 2011. In accordance with the
Figure 2 Unadjusted and adjusted effects of a history of ischaemic heart disease on the hazard of all-cause mortality. *Age
cohorts consisted of cases who had a history of acute myocardial infarction (AMI) and controls who had no history of AMI. The
hazard of mortality associated with single/multiple AMIs includes possible history of angina. **Adjusted for sex, year of birth,
socioeconomic status, heart failure, other cardiovascular conditions, chronic kidney disease (only at ages 70 and 75), diabetes,
hypertension, hypercholesterolaemia, coronary revascularisation, statins, β-blockers, ACE inhibitors, calcium-channel blockers,
aspirin, alcohol consumption, body mass index, smoking status, and general practice.
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literature, this study found that AMI survivors have a
long term, increased hazard of mortality, in which
younger survivors and survivors of multiple events were
worse off.1 2 5 7–12 However, this study estimated lower
hazards of mortality than previously estimated. Survival
was better in those who had coronary revascularisation
or were prescribed statins or β-blockers, but worse in
those prescribed aspirin or ACE inhibitors, and
unchanged in those prescribed calcium-channel block-
ers. The estimated hazards of mortality associated with
these treatments were almost the same at each age,
implying that the effectiveness of treatments does not
differ by age.
The lower estimated hazards of mortality associated
with a history of AMI reported by this study compared
with previous studies could be due to the different data
Figure 3 Adjusted effects of a
history of treatment on the hazard
of all-cause mortality.
*Time-varying effect of a history
of coronary revascularisation on
the hazard of mortality was split
at 5 years of FU after the initial
age. **Adjusted for sex, year of
birth, socioeconomic status, AMI,
angina, heart failure, other
cardiovascular conditions, chronic
kidney disease (only at ages 70
and 75), diabetes, hypertension,
hypercholesterolaemia, alcohol
consumption, body mass index,
smoking status, general practice,
and listed treatments. Results of
β-blockers and calcium-channel
blockers are reported separately
for cases and controls, because
there was an interaction effect.
AMI, acute myocardial infarction;
Ca-channel, calcium-channel;
FU, follow-up; revasc.,
revascularisation; yrs, years.
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source used and the range of confounders adjusted for.
This study made use of primary care data, whereas most
studies used hospital and register data. Research showed
that the 1-year mortality rate of AMI is lower in primary
care probably because of a lower proportion of severe
cases.16 Furthermore, this study adjusted for a range of
confounders which attenuated the estimated hazards of
mortality associated with a history of AMI. There is a
smaller difference between the unadjusted estimates of
this study and the age-standardised and sex-standardised
mortality ratios estimated in English residents based on
hospital and register data from 2004 to 2010 by Smolina
et al.5 It is unlikely that the lower estimated hazards of
mortality reported by this study are due to the shifting
epidemiological trends in cardiovascular disease because
there were no interactions between a history of AMI and
year of birth category or other risk factors with the
exception of angina, β-blockers, and calcium-channel
blockers. The medical advances and shifting prevalence
of risk factors over time were adjusted for in the analysis
and had no different survival effects in AMI patients
compared with patients without AMI. This study did not
ﬁnd sex difference in survival prospects after AMI.
This is supported by some studies8 10 33 34 but contra-
dicted by another.5 The difference could be explained
by (the lack of) adjustment for comorbidities and
treatments.8 10 33 34
This study found that the lower uptake of coronary
revascularisation by women could not be explained by
age, diabetes, or deprivation, as suggested by a previous
study.10 A study with data from the UK from 2003 to 2008
showed that coronary revascularisation was more preva-
lent in non-STEMIs than in STEMIs.19 As non-STEMIs
are more common among women than among men,19 it
seems that type of AMI could not explain the sex differ-
ence in uptake of surgery present in this study. In 2012,
the European Society for Cardiology reviewed the sex dif-
ferences in treatment after AMI, taking into account sex
differences in risk proﬁles, and concluded that sex differ-
ences exist.35 This study also found that a history of cor-
onary revascularisation was no longer associated with a
signiﬁcantly improved survival prospects after 5 years of
follow-up. This is in accordance with another study that
reported a protective effect in the 1-year mortality rate
but an insigniﬁcant effect in the 5-year mortality rate of
AMI.10 The ﬁndings suggest that coronary revascularisa-
tion might mainly be beneﬁcial in reducing early mortal-
ity. No sex difference in survival after coronary
revascularisation was found in this study, which is sup-
ported by some studies5 10 but contradicted by another.36
This study found no difference in drugs prescriptions by
sex by 2010, suggesting that the difference converged
over time.3
The ﬁndings of this study agree with the clinical evi-
dence reviewed by NICE23 on the effectiveness of statins
and calcium-channel blockers, but disagree with the
effectiveness of ACE inhibitors, aspirin, and β-blockers.
The NICE review on ACE inhibitors estimated a
protective effect in AMI patients with left ventricular
systolic dysfunction (LVSD) and an inconclusive harmful
effect in AMI patients with unselected LVSD in
1986–1993.37–41 Other studies not yet reviewed by NICE,
estimated hazardous effects associated with ACE
inhibitors and suggested that the results could be due to
confounding by heart failure or indication and use of
old data (1984–2005).1 12 42 The current study con-
trolled for heart failure, which lowered the HR of ACE
inhibitors by ∼0.05, and made used of more recent data
from 1987 to 2011, thereby suggesting that ACE inhibi-
tors might in fact be harmful to survival. The NICE
review on aspirin only included one study that estimated
an inconclusive protective effect of the drug versus
placebo on all-cause mortality.23 That study included
men with a recent AMI aged 30–64 in 1972–1974.43 The
current study made use of more recent data with longer
follow-up of older patients of both sexes. Aspirin is asso-
ciated with an increased risk of bleeding, where the risk
increases with age.23 Since the elderly are excluded from
most clinical trials, it could be that aspirin might actually
be harmful in the elderly as the ﬁndings of the current
study suggest. The ﬁndings on β-blockers are in concord-
ance with more recent published clinical studies1 11 42
that were not yet reviewed by NICE.
Finally, this study found that survival prospects varied
greatly across general practices, which was independent
from health status, ethnic background, deprivation,
urbanisation, and pollution. Other studies have not
reported survival variations by general practice, although
it was adjusted for in a study by Gerber et al.9 That study
estimated the effect of neighbourhood and individual
socioeconomic status on survival after AMI and sug-
gested that higher level measured socioeconomic status
might capture residual confounding of unequal hospital
resources and social characteristics of an area such as
social cohesion and attitudes towards health.9
Study’s strengths and limitations
This study used routinely collected primary care data
that were representative of the UK.17 18 The advantage
of using primary care data was that there was more infor-
mation on sociodemographic and lifestyle factors avail-
able and there was a higher coverage of AMI cases.16
The matched study design allowed to estimate the effect
of a history of AMI on mortality compared with no
history of AMI while adjusting for a wide range of con-
founders. The confounders included comorbidities,
treatments, lifestyle choices, and demographics, and
interactions between these factors. This has not been
done before; previous studies were either population-
based which has a tendency to overestimate the hazard-
ous effect of AMI on survival, or previous studies only
included AMI cases which meant that only survival varia-
tions among AMI survivors could be estimated.
Estimating the effect of a history of AMI at different
ages meant that the results could be used for planning
ongoing medical management and planning resources
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allocation in the British population. Finally, the study
had a long follow-up of almost 25 years.
Data on the type of AMI were not available in THIN,
therefore this study could not distinguish between
STEMI and non-STEMI and thus could not provide spe-
ciﬁc survival prospects for them. Although the major
confounders of AMI were adjusted for, there could
potentially be some residual confounding by a number
of other factors: family history of AMI or cardiovascular
disease, psychosocial factors, fruit and vegetable intake,
and physical activity. These factors were not adjusted for
in the survival models due to the unsystematic or no
recording in the medical records. AMI severity indica-
tors, such as left ventricular function, were also not
included in the survival models because this information
was only available for the cases and not the controls.
Missing data in lifestyle factors were dealt with by mul-
tiple imputations. This is a widely accepted method to
deal with bias and imprecision when missing data are
present.28 Adherence to drug therapy was unknown and
therefore the survival prospects associated with prescrip-
tion of drug therapy might not accurately reﬂect the
effect of the drugs themselves on mortality.
Furthermore, no dose–response effect could be esti-
mated as the prescribed doses were not included in the
survival models. Finally, there might be bias by indica-
tion in which patients receiving treatment were
somehow sicker than those not receiving the treatment,
despite the adjustment for important confounders.
Recommendations
The ﬁndings of this study suggest that surviving an AMI
is associated with a permanent increased hazard of mor-
tality and that coronary revascularisation, statins pre-
scription, and β-blockers prescription can reduce this
hazard. This is of clinical importance, because not every
AMI survivor receives these treatments. In 2010,
β-blockers were not widely prescribed to AMI survivors;
the survival prospects of 35% of the AMI survivors might
be improved by such a prescription. This study suggested
that there were sex and deprivation inequalities in
uptake of coronary revascularisation while all subgroups
beneﬁtted equally from it.
This study also found that the prescription of aspirin
and/or ACE inhibitors was associated with an increased
hazard of mortality. This might be of potential concern
as the previous explanations for similar ﬁndings on the
hazardous effects associated with ACE inhibitors on sur-
vival, such as confounding by heart failure and use of
old data, were addressed by this study. By 2010, 94% and
85% of AMI survivors were prescribed aspirin and ACE
inhibitor, respectively. Further research is required to
assess the effectiveness of aspirin and ACE inhibitors in
the light of our ﬁndings that such commonly used medi-
cations may be of little beneﬁt, or even cause harm.
Further research is needed to explore the reasons for
the considerable unexplained survival variations
between general practices.
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